MST Mundipharma - a new preparation for the treatment of pain in oncological patients

flag

Klin Onkol 1994; 7(6): 180-181.

Summary: The experiences with the medicine MST Mundipharma Basel are described. The analgetic activity of MST Mundipharma lasted at least 12 hours in the group of 10 patients. The adverse effects of MST Mundipharma (nausea and obstipation) were smaller compared with parenteral route of application. We conclude, that MST Mundipharma is contribution to the paliative care of cancer patient.